<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092284</url>
  </required_header>
  <id_info>
    <org_study_id>CSCC_ASCII</org_study_id>
    <nct_id>NCT03092284</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Therapy in Heart Failure</brief_title>
  <acronym>CSCC_ASCII</acronym>
  <official_title>Allogeneic Adipose Tissue-derived Stromal/Stem Cell Therapy in Patients With Ischemic Heart Disease and Heart Failure: A Phase II Danish Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JKastrup</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present aim is to perform at clinical double-blind placebo-controlled Cardiology Stem
      Cell Centre - Adipose Stem Cells (CSCC_ASC) study in heart failure patients to investigate
      the regenerative capacity of the CSCC_ASC treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to investigate the regenerative capacity of direct intra-myocardial
      injection of 100 mio. allogeneic CSCC_ASCs in patients with reduced left ventricular Ejection
      Fraction (EF) (≤45%) and heart failure in a double-blind placebo-controlled design.

      A total of 81 patients with will be enrolled in the study and treated in a 2:1 randomization
      with either CSCC_ASC or placebo (saline).

      The primary endpoint is change in left ventricle end-systolic volume (LVESV) at 6 months
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in left ventricle end-systolic volume (LVESV) from base line to 6 months follow-up measured by echocardiography and computerized tomography</measure>
    <time_frame>6 months</time_frame>
    <description>change in left ventricle end-systolic volume (LVESV) from base line to 6 months follow-up measured by echocardiography and computerized tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Safety is evaluated by the incidence and severity of serious adverse events and suspected unrelated serious adverse events at 12 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy left ventricle</measure>
    <time_frame>6 months</time_frame>
    <description>change in left ventricle ejection fraction (EF) measured by echocardiography and computerized tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy clinical function assessed by change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to 6 months follow-up</measure>
    <time_frame>6 months</time_frame>
    <description>change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to 6 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy clinical function assessed by change in Seattle Angina Questionnaire and 6 min walking test from baseline to 6 months follow-up</measure>
    <time_frame>6 months</time_frame>
    <description>change in Seattle Angina Questionnaire and 6 min walking test from baseline to 6 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy clinical function assessed by change in 6 min walking test from baseline to 6 months follow-up</measure>
    <time_frame>6 months</time_frame>
    <description>change in 6 min walking test from baseline to 6 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy clinical function assessed by change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to 12 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy clinical function assessed by change in Seattle Angina Questionnaire and 6 min walking test from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>change in Seattle Angina Questionnaire and 6 min walking test from baseline to 12 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy clinical function assessed by change in 6 min walking test from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>change in 6 min walking test from baseline to 12 months follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allogeneic adipose derived stromal cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)</intervention_name>
    <description>Direct intramyocardial injection of CSCC_ASC</description>
    <arm_group_label>Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 30 to 80 years of age

          2. Signed informed consent

          3. Chronic stable ischemic heart disease

          4. Symptomatic heart failure - New York Heart Association (NYHA) class II-III

          5. EF ≤45%

          6. Plasma NT-pro-BNP &gt; 300 pg/ml (&gt; 35 pmol/L) in sinus rhythm and plasma NT-pro-BNP &gt;
             422 pg/ml (&gt; 450 pmol/L) in patients with atrial fibrillation

          7. Maximal tolerable heart failure medication

          8. Medication unchanged two months prior to inclusion

          9. No option for percutaneous coronary intervention (PCI) or coronary artery bypass graft
             (CABG)

         10. Patients who have had PCI or CABG within six months of inclusion must have a new
             angiography less than one month before inclusion or at least four months after the
             intervention to rule out early restenosis

         11. Patients cannot be included until three months after implantation of a cardiac
             resynchronisation therapy device

        Exclusion Criteria:

          1. Heart Failure (NYHA I or IV)

          2. Acute coronary syndrome with elevation of creatine kinase (CK) isoenzyme MB (CKMB) or
             troponins, stroke or transitory cerebral ischemia within six weeks of inclusion

          3. Other revascularisation treatment within four months of treatment

          4. If clinically indicated the patient should have a coronary angiography before
             inclusion

          5. Moderate to severe aortic stenosis (valve area &lt; 1.3 mm2) or valvular disease with
             option for surgery.

          6. Diminished functional capacity for other reasons such as: obstructive pulmonary
             disease (COPD) with forced expiratory volume (FEV) &lt;1 L/min, moderate to severe
             claudication or morbid obesity

          7. Clinical significant anaemia (haemoglobin &lt; 6 mmol/L), leukopenia (leucocytes &lt; 2
             109/L), leucocytosis (leucocytes &gt;14 109/L) or thrombocytopenia (thrombocytes &lt; 50
             109/L)

          8. Anticoagulation treatment that cannot be paused during cell injections

          9. Patients with reduced immune response

         10. History with malignant disease within five years of inclusion or suspected malignity -
             except treated skin cancer other than melanoma

         11. Pregnant women

         12. Other experimental treatment within four weeks of baseline tests

         13. Participation in another intervention trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Kastrup, Professor MD</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Kastrup, Professor MD</last_name>
    <phone>+4535452819</phone>
    <email>jens.kastrup@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiac Catheterization Laboratory 2014, The Heart Centre, University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Kastrup, MD DMSc</last_name>
      <phone>+4535452817</phone>
      <email>jkastrup@rh.hosp.dk</email>
    </contact>
    <investigator>
      <last_name>Jens Kastrup, MD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>JKastrup</investigator_full_name>
    <investigator_title>Professor Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data can be share for scientific collaboration</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

